Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group

By sjmartinez • November 3, 2023

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R; OMERACT Safety Working Group. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum. 2023 Oct 26;63:152288. doi: 10.1016/j.semarthrit.2023.152288. Epub ahead of print. PMID: 37918049.

Tags: Adverse events, Core outcome set, Harms, OMERACT, Publications, Rheumatology, rheumatology, safety

Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

Li YR, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, Zhang B, Yang Y, Shen X, Chen Y, Hsiai[...]

JPEN Journal Club 99. ICEMAN analyses

Koretz RL. JPEN Journal Club 99. ICEMAN analyses. JPEN J Parenter Enteral Nutr. 2026 Mar 17. doi: 10.1002/jpen.70072. Epub ahead of print. PMID: 41846318.

A Double-blind Randomized Trial of Oral Chlorhexidine Gluconate for Treatment of Oral Staphylococcus aureus Colonization in Healthy Children

Liu L, Launer B, Flores E, Tchakalian G, Kreiswirth B, Bolaris M, Kim T, Young KD, Miller LG. A Double-blind Randomized Trial of Oral Chlorhexidine[...]